Albany Molecular Research, Inc. 

(Public, NASDAQ:AMRI)   Watch this stock   
Find more results for AMRI
Nov 9, 2009
Q3 2009 Earnings Conference Call
Nov 9, 2009
Q3 2009 Earnings Release
Nov 3, 2009
Oppenheimer & Co. Healthcare Conference
Sep 22, 2009
UBS Global Life Sciences Conference
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin 0.35% 8.97%
Operating margin 0.75% 11.32%
EBITD margin - 19.05%
Return on average assets 0.18% 5.29%
Return on average equity 0.22% 6.22%
Employees 1,357 -

Address

21 Corporate Circle PO Box 15098
Albany, NY 12212
United States - Map
+1-518-4640279 (Phone)
+1-518-4640289 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Albany Molecular Research, Inc. discussions

  View all discussions »

Description

Albany Molecular Research, Inc., provides scientific services, technologies and products. The Company's core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing, and a separate, stand-alone research and development division consisting of technology investments, internal drug discovery and niche generic active pharmaceutical ingredient product development. With locations in the United States, Europe and Asia, the Company provides customers with a range of services and cost models. In January 2008, the Company completed the acquisition of FineKem Laboratories Pvt. Limited (FineKem), a manufacturing facility in Aurangabad, India.

Officers and directors

Thomas E. D' Ambra Ph.D.
Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation - Reuters
Mark T. Frost
Chief Financial Officer, Senior Vice President - Administration, Treasurer
Age: 45
Bio & Compensation - Reuters
W. Steven Jennings
Senior Vice President - Sales, Marketing and Business Development
Age: 57
Bio & Compensation - Reuters
Steven Hagen Ph.D.
Vice President - Pharmaceutical Development and Manufacturing
Age: 48
Bio & Compensation - Reuters
Anthony P. Tartaglia M.D.
Lead Independent Director
Age: 76
Bio & Compensation - Reuters
Kevin O' Connor
Director
Age: 54
Bio & Compensation - Reuters
Paul S. Anderson Ph.D.
Director
Age: 70
Bio & Compensation - Reuters
Arthur J. Roth
Director
Age: 69
Bio & Compensation - Reuters
Veronica G.H. Jordan Ph.D.
Director
Age: 58
Bio & Compensation - Reuters